A Preliminary Study on Establishing the Set of Terms for Coding Clinical Trials of TCM Based on MedDRA Terminology

Abstract

CLC Number:

LI Qing-na,LU Fang,ZHAO Yang,GAO Hong-yang,GAO Rui. A Preliminary Study on Establishing the Set of Terms for Coding Clinical Trials of TCM Based on MedDRA Terminology[J]. Chinese Journal of Pharmacovigilance, 2015, 12(1): 53-55.

References

[1] 国家食品药品监督管理总局.药物临床试验机构资格认定公告（第3号）[EB/OL].(2013-12-30)[2014-05-03].http://www.sda.gov.cn/WS01/CL0069/95894.html.
[2] 胡镜清，吴圣贤，翟华强，等.病例报告表规范化与电子化研究现状及其中医药标准系统构建原则[J].中国中医药信息杂志，2006，13(9)：1-2．
[3] ICH. MedDRA入门指南. Version17.0[EB/OL].(2014-03)[2014-04-08].https://www.meddra.org/how-to-use/support-documentation.
[4] ICH.Coding with MedDRA[EB/OL].(2014-03-19)[2014-04-08]. http://www.meddra.org/training-materials.
[5] 侯永芳.乌普萨拉监测中心在Vigibase 数据库中应用MedDRA术语集[J]. 中国药物警戒， 2008，5（4）：242-243.
[6] 国家食品药品监督管理局药品审评中心. 中药新药临床研究一般原则(征求意见稿)[EB/OL].(2012-11-27)[2014-03-04].http://www.cde.org.cn/news.do?method=largeInfo&id=312877.
[7] 国家技术监督局.中华人民共和国国家标准中医病证分类与代码(GB/T15657-1995) [S/OL].(1995-07-25)[2014-04-12]. http://www.spsp.gov.cn/DataCenter/Standard/PDFView.aspx?ca=BFtxVgt4KOY.
[8] 国家技术监督局.中华人民共和国国家标准中医临床诊疗术语-证候部分（GB/T16751.2-1997）[S/OL].(1997-03-04)[2014-04-12].http://www.spsp.gov.cn/DataCenter/Standard/PDFView.aspxca=7T4LxkUZcag.
[9] 国家食品药品监督管理局药品审评中心.中药、天然药物治疗冠心病心绞痛临床研究技术指导原则[EB/OL].(2011-12-08)[2013-01-24].http://www.cde.org.cn/zdyz.do?method=largePage&id=120.
[10] 国家技术监督局.中华人民共和国国家标准中医临床诊疗术语治法部分（GB/T 16751.3-1997）[S/OL].(1997-03-04)[2014-04-12].http://www.spsp.gov.cn/DataCenter/Standard/PDFView.aspxca=aRiQB3WmFng.

[1]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[2]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[3]	BAI Zhaofang, ZHAN Xiaoyan, YAO Qing, CHEN Simin, ZHAO Xu, XIAO Xiaohe. Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine: disease-syndrome-based toxicology [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 6-14.
[4]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[5]	GAO Yuan, SHI Wei, XIAO Xiaohe, BAI Zhaofang, WANG Jiabo. Research progress on the animal models of idiosyncratic drug-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 33-39.
[6]	ZHANG Jingsheng, JI Zuen, PANG Bo, XU Yingli, CAO Shan, ZHANG Yu, SUN Qiyue, SUN Jing, LI Shuran, ZHANG Wei, ZHAO Ronghua, CUI Xiaolan. Discussion on traditional Chinese medicine theory and modern pharmacology of Xuanfei Baidu decoction for treating novel coronavirus infection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 55-58.
[7]	LI Shuran, GUO Shanshan, JI Zuen, ZHANG Wei, CUI Xiaolan. Research status of cognitive dysfunction after SARS-CoV-2 infection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 59-64.
[8]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[9]	MA Ruize, CHEN Zhihai. The latest progress of small molecule anti-SARS-CoV-2 drugs [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 961-966.
[10]	SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
[11]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[12]	HE Jia, JIN Yan, ZHAO Yuyang, ZHOU Junhui, LI Xiaolin, YUAN Yuan, FU Lu. Research progress in methods for toxicity-decreasing processing of toxic herbal traditional Chinese medicines [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1064-1070.
[13]	DING Zihe, ZHANG Yanqiong, LIN Na. Component-effect/toxicity-target correlations of Tripterygium wilfordii in terms of lipid metabolism [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 489-495.
[14]	LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping. Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
[15]	SHEN Pan, SUN Dezhi, ZHOU Wei, GAO Yue. Research progress in toxicity prediction of traditional Chinese medicines [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 473-479.